ABC Arbitrage SA Has $1.71 Million Stake in Evotec AG $EVO

ABC Arbitrage SA lifted its position in shares of Evotec AG (NASDAQ:EVO) by 319.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 554,287 shares of the company’s stock after purchasing an additional 422,230 shares during the period. ABC Arbitrage SA’s holdings in Evotec were worth $1,707,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE increased its position in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the period. Thrivent Financial for Lutherans bought a new position in Evotec during the 3rd quarter worth $53,000. XTX Topco Ltd acquired a new stake in shares of Evotec during the second quarter worth $66,000. Finally, Snowden Capital Advisors LLC acquired a new stake in shares of Evotec during the second quarter worth $122,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EVO has been the topic of several research reports. HC Wainwright initiated coverage on shares of Evotec in a research note on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price target on the stock. Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Finally, Berenberg Bank began coverage on shares of Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Evotec Price Performance

NASDAQ:EVO opened at $3.06 on Tuesday. Evotec AG has a fifty-two week low of $2.31 and a fifty-two week high of $4.80. The company has a current ratio of 1.68, a quick ratio of 1.60 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $2.83 and a 200-day moving average price of $3.20.

Evotec (NASDAQ:EVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. The company had revenue of $297.02 million for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%. As a group, research analysts forecast that Evotec AG will post -0.63 earnings per share for the current year.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.